

**Spire Healthcare Group plc**

8 April 2025

## 2024 Annual Report and 2025 Notice of Annual General Meeting

Spire Healthcare Group plc (the 'Company') released its preliminary announcement of its annual results for the year ended 31 December 2024 ('Preliminary Announcement') on Thursday, 6 March 2025.

Further to that Preliminary Announcement, the Company confirms that its Annual Report and Accounts for the year ended 31 December 2024 ('2024 Annual Report'), 2025 Notice of Annual General Meeting and Form of Proxy have now been published. Printed copies have been posted to shareholders who have requested hard copies.

The following documents are available on the Company's website:

2024 Annual Report: [www.spirehealthcare.com/AR2024](http://www.spirehealthcare.com/AR2024)  
2025 Notice of Meeting: [www.spirehealthcare.com/Notice2025](http://www.spirehealthcare.com/Notice2025)

In accordance with the Financial Conduct Authority's ('FCA') Listing Rule 6.4.1R, the Company will submit its 2024 Annual Report and other shareholder documents to the National Storage Mechanism. These documents should be available for inspection within two working days at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

In accordance with the FCA's Disclosure and Transparency Rules ('DTRs') the regulated information required to be communicated under DTR 6.3.5R(1A) is available in unedited full text within the 2024 Annual Report which will be available both on the National Storage Mechanism and on the Company's website [www.spirehealthcare.com](http://www.spirehealthcare.com).

## Arrangements for the Annual General Meeting

The Annual General Meeting of the Company will be held at 11.00am on Wednesday, 14 May 2025 at 3 Dorset Rise, London EC4Y 8EN (the '2025 AGM').

The Company welcomes shareholders to attend the 2025 AGM in person, but they are asked to monitor the Company's website should any changes in requirements on attending the meeting be necessary.

The Board always welcomes questions from shareholders, and we request that these are submitted by e-mail to [companysecretary@spirehealthcare.com](mailto:companysecretary@spirehealthcare.com). Answers to questions received will be placed on the Company's website ahead of the meeting.

Details of the resolutions to be proposed at the 2025 AGM are set out in the 2025 Notice of Meeting. The voting results of all resolutions put before the 2025 AGM will be announced to the market following the meeting.

## Enquiries

Amie Gramlick  
Director of Investor Relations

## About Spire Healthcare

Spire Healthcare is a leading independent healthcare group in the United Kingdom, running 38 hospitals and over 50 clinics, medical centres and consulting rooms across England, Wales and Scotland. It operates a network of private

Spire, medical services and consulting teams across England, Wales and Scotland. It operates a network of private GPs and provides occupational health services to over 800 corporate clients.

Working in partnership with over 8,600 experienced consultants, Spire Healthcare delivered tailored, personalised care to over 1 million inpatients, outpatients and daycase patients, and occupational health programme clients, in 2023, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom. It also delivers a range of private and NHS mental health, musculoskeletal and dermatological services under the Vita Health Group brand.

Spire Healthcare's well-located and scalable hospitals have delivered successful and award-winning outcomes, positioning the group well with patients, consultants, the NHS, GPs and Private Medical Insurance ('PMI') providers. 98% of Spire Healthcare's inspected locations are rated 'Good,' 'Outstanding' or the equivalent by health inspectors in England, Wales and Scotland.

Spire Healthcare is listed on the London Stock Exchange and is a member of the FTSE 250.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSSSUFFAEISEEL